Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-131782
Filing Date
2026-03-30
Accepted
2026-03-30 17:30:31
Documents
81
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K annx-20251231.htm   iXBRL 10-K 3380945
2 EX-4.3 annx-ex4_3.htm EX-4.3 59767
3 EX-10.16 annx-ex10_16.htm EX-10.16 435459
4 EX-23.1 annx-ex23_1.htm EX-23.1 3829
5 EX-31.1 annx-ex31_1.htm EX-31.1 19318
6 EX-31.2 annx-ex31_2.htm EX-31.2 19340
7 EX-32.1 annx-ex32_1.htm EX-32.1 17754
8 GRAPHIC img189330953_0.jpg GRAPHIC 271857
9 GRAPHIC img189330953_1.jpg GRAPHIC 29242
10 GRAPHIC img189330953_2.gif GRAPHIC 57738
11 GRAPHIC img189330953_3.gif GRAPHIC 54597
12 GRAPHIC img189330953_4.gif GRAPHIC 483987
  Complete submission text file 0001193125-26-131782.txt   14494306

Data Files

Seq Description Document Type Size
13 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT annx-20251231.xsd EX-101.SCH 1337609
85 EXTRACTED XBRL INSTANCE DOCUMENT annx-20251231_htm.xml XML 2042494
Mailing Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005
Business Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005 (650) 822-5500
Annexon, Inc. (Filer) CIK: 0001528115 (see all company filings)

EIN.: 275414423 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39402 | Film No.: 26813141
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)